Key result
Perioperative dexamethasone administration did not reduce postoperative length of stay compared to no dexamethasone in trauma patients undergoing tibial or femoral intramedullary nailing (2.0 vs 2.1 days).
Why the study?
Does perioperative dexamethasone reduce postoperative length of stay in trauma patients undergoing femoral or tibial intramedullary nailing?
Cohort (n=201)
No
Does perioperative dexamethasone reduce postoperative length of stay in trauma patients undergoing femoral or tibial intramedullary nailing?
Absolute Event Rate: 2% vs 2.1%
Perioperative dexamethasone does not significantly reduce length of stay in trauma patients undergoing tibial or femoral intramedullary nailing, though it may offer short-term benefits without increasing adverse events.
Background: Corticosteroids are frequently administered perioperatively during arthroplasty procedures with reported reductions in length of stay (LOS), postoperative pain & nausea, and opioid consumption. This investigation aims to evaluate the effects of perioperative dexamethasone on LOS, post-operative outcomes, and adverse event rates for trauma patients undergoing femoral/tibial intramedullary nailing (IMN). Methods: A retrospective cohort study was conducted at an urban Level 1 Trauma center between May 2018 and May 2022. 201 patients aged 16-65 with isolated femur or tibia fractures treated with antegrade or retrograde femoral or tibial IMN underwent chart review. Those with mental or physical disability, GFR <30, liver disease, poorly controlled diabetes (HbA1C ≥ 8), or steroid use within 3 months were excluded. Patients with both open and closed fractures were included in the study. LOS postoperatively was compared between patients who received dexamethasone perioperatively (Dex, n = 88) and those who did not (No Dex, n = 113). Secondary outcomes pertained to inpatient admission (e.g. average pain score), time to union, incidence of nonunion by 6 months, and 90-day surgical site infection rate. Categorical outcomes were analyzed using Wilcoxon rank-sum analysis and dichotomous data using chi-square testing. Results: There was no difference in LOS between groups (Dex 2.0 ± 1.6 days, No Dex 2.1 ± 1.3 days). While the Dex group had lower rates of superficial infection (Dex 0 % [0/43], No Dex 13.5 % [5/37]), opioid consumption (morphine milligram equivalent [MME]) on postoperative day 0 (Dex 16.7 ± 16.1, No Dex 21.1 ± 17.4), and MME POD0-3 average (Dex 24.5 ± 16.5, No Dex 30.5 ± 18.3), these results were not statistically significant. There were no differences in other secondary outcomes, including time to union, pain scores, average blood glucose, and complication rates. Conclusion: Despite previous literature supporting a reduction in LOS associated with perioperative dexamethasone administration, the current study demonstrated no difference in trauma patients undergoing tibial or femoral IMN. However, perioperative administration may provide short-term benefits without increasing adverse event rate.
No takes yet. Share an insight, caveat, or question.
Dagher et al. (2025) conducted a cohort in Isolated femur or tibia fractures (n=201). Perioperative dexamethasone vs. No dexamethasone was evaluated on Length of stay (LOS) postoperatively. Perioperative dexamethasone administration did not reduce postoperative length of stay compared to no dexamethasone in trauma patients undergoing tibial or femoral intramedullary nailing (2.0 vs 2.1 days).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: